# TEST_READY: Drugph Clinical Decision Support System (CDSS) E2E Test Suite

## Executive Summary

The End-to-End (E2E) Test Suite for the Drugph Clinical Decision Support System has been designed, implemented, and verified in accordance with the project charter and `ORIGINAL_REQUEST.md` (Requirements R1 and R2).

- **Total E2E Tests**: 38 tests across 2 comprehensive test suites
- **Test Pass Rate**: **100% (38/38 passed)**
- **Static Analysis**: **0 issues (`dart analyze test/e2e/` passed cleanly)**
- **Testing Philosophy**: Opaque-box, requirement-driven, deterministic derivation from international clinical pharmacology consensus standards (ASHP 2020, Sanford Guide, Lexicomp, DiPiro, Rowland & Tozer, Winter, Bauer, Sheiner-Tozer, Michaelis-Menten).

---

## 4-Tier Test Matrix & Coverage Summary

### 1. `test/e2e/e2e_pkpd_modeling_test.dart` (Requirement R1: PK-PD Modeling Engine)

| Tier | Test ID | Description | Clinical / Mathematical Verification | Status |
|---|---|---|---|---|
| **Tier 1** | 1.1 | 1-Comp IV Bolus | Single-dose mono-exponential decay $C(t) = \frac{D}{V_d} e^{-k_e t}$, initial peak $C_0$, analytical $\text{AUC}_{0 \to \infty} = \frac{D}{Cl}$ | **PASS** |
| **Tier 1** | 1.2 | 1-Comp IV Intermittent Infusion | Infusion phase ($0 \le t \le T_{\inf}$) and elimination phase ($t > T_{\inf}$); verifies steady-state peak/trough against `TdmCalculator` | **PASS** |
| **Tier 1** | 1.3 | 1-Comp Oral Extravascular | Bateman absorption equation, analytical $T_{\max} = \frac{\ln(k_a/k_e)}{k_a - k_e}$, peak concentration $C_{\max}$, derivative zero-crossing | **PASS** |
| **Tier 1** | 1.4 | 1-Comp Continuous IV Infusion | Zero-order inflow $k_0$, asymptotic steady-state $C_{ss} = \frac{k_0}{Cl}$, half-life fractions ($50\% C_{ss}$ at $1 \times t_{1/2}$, $90\%$ at $3.32 \times t_{1/2}$) | **PASS** |
| **Tier 1** | 1.5 | 2-Comp Disposition & Biexponential | Micro-to-macro parameter conversion ($k_{10}, k_{12}, k_{21} \to \alpha, \beta, A, B$), $C_0 = A + B = \frac{D}{V_c}$, total $\text{AUC} = \frac{A}{\alpha} + \frac{B}{\beta} = \frac{D}{Cl}$ | **PASS** |
| **Tier 1** | 1.6 | Multi-Dose Accumulation | Accumulation factor $R = \frac{1}{1 - e^{-k_e \tau}}$, finite accumulation $R_N$, steady-state convergence over $N$ cycles | **PASS** |
| **Tier 1** | 1.7 | Therapeutic Window Classifications | Classifies concentrations into Sub-therapeutic ($< \text{MEC}$), Therapeutic Window, and Toxic/Overdose ($> \text{MTC}$) complying with Rule 5 | **PASS** |
| **Tier 2** | 2.1 | Bateman Singularity ($k_a = k_e$) | Eliminates $0/0$ indeterminate form via exact L'Hôpital limit $C(t) = \frac{F D k_e}{V_d} t e^{-k_e t}$, $T_{\max} = 1/k_e$, $C_{\max} = \frac{F D}{V_d e}$ | **PASS** |
| **Tier 2** | 2.2 | Anuria / Zero Renal Clearance | $CrCl = 0\text{ mL/min}$ evaluates baseline non-renal elimination ($k_e = 0.0044\text{ hr}^{-1}$, $t_{1/2} \approx 157.5\text{ hr}$) without division by zero | **PASS** |
| **Tier 2** | 2.3 | Augmented Renal Clearance (ARC) | Hyperdynamic sepsis ($CrCl = 180\text{ mL/min}$), accelerated $k_e = 0.1538\text{ hr}^{-1}$, short $t_{1/2} = 4.51\text{ hr}$, sub-therapeutic trough alert | **PASS** |
| **Tier 2** | 2.4 | Flip-Flop Kinetics ($k_a < k_e$) | Sustained-release formulations where absorption rate limits elimination rate; maintains curve continuity and evaluates $T_{\max}$ | **PASS** |
| **Tier 2** | 2.5 | Infusion Duration Boundary ($T_{\inf} \to 0$) | Micro-infusion smoothly converges to IV bolus formula within $0.001\%$ without numerical explosion | **PASS** |
| **Tier 2** | 2.6 | Invalid Infusion Duration ($T_{\inf} \ge \tau$) | Enforces intermittent infusion invariant; throws descriptive `ArgumentError` | **PASS** |
| **Tier 2** | 2.7 | Rule 5 Non-Blocking Overdose Invariant | Supratherapeutic dose (5,000 mg Vancomycin) displays true peak ($C_{\max} > 140\text{ mg/L}$) and red alert without zeroing/clamping | **PASS** |
| **Tier 3** | 3.1 | Oral vs IV Intermittent Comparison | Synchronized time-horizon comparison generating delta metrics ($\Delta C_{\max}, \Delta C_{\min}, \Delta \text{AUC}_{24}$) and bioavailability ratio | **PASS** |
| **Tier 3** | 3.2 | Clearance Slider Dynamics | Clearance slider increments (30, 60, 90, 120 mL/min) dynamically shorten half-life and reduce steady-state trough monotonically | **PASS** |
| **Tier 4** | 4.1 | Digoxin 2-Comp Distribution Hazard | Blood draw at $1.5\text{h}$ demonstrates pseudo-toxic central peak ($> 5.0\text{ ng/mL}$) with alert; $8.0\text{h}$ draw confirms true equilibrium | **PASS** |
| **Tier 4** | 4.2 | Continuous Infusion Titration | Step-up titration from $30\text{ mg/hr}$ to $60\text{ mg/hr}$ simulating dynamic approach to new steady-state from non-zero initial concentration | **PASS** |

---

### 2. `test/e2e/e2e_specialized_dosing_test.dart` (Requirement R2: Specialized Dosing Engine)

| Tier | Test ID | Description | Clinical / Mathematical Verification | Status |
|---|---|---|---|---|
| **Tier 1** | 1.1 | Vancomycin AUC24/MIC Target | ASHP 2020 target ratio $400–600\text{ mg}\cdot\text{h/L}$ for $\text{MIC} = 1.0$; flags subtherapeutic $< 400$ and nephrotoxic AKI risk $> 600$ | **PASS** |
| **Tier 1** | 1.2 | Aminoglycosides Hartford & Conventional | Hartford 7 mg/kg 6–14h window; Amikacin normalization by dividing by 2.0; conventional peak ($6–10\text{ mcg/mL}$) and trough ($< 1–2\text{ mcg/mL}$) | **PASS** |
| **Tier 1** | 1.3 | Phenytoin Michaelis-Menten Kinetics | Capacity-limited kinetics ($V_{\max} = 7\text{ mg/kg/day}, K_m = 4\text{ mg/L}$); demonstrates non-linear concentration surge with small dose increase | **PASS** |
| **Tier 1** | 1.4 | Sheiner-Tozer & Winter-Tozer Equations | Albumin correction in hypoalbuminemia ($C_{adj} = \frac{C_{obs}}{0.2 \cdot Alb + 0.1}$) and ESRD / $CrCl < 20$ ($C_{adj} = \frac{C_{obs}}{0.1 \cdot Alb + 0.1}$) | **PASS** |
| **Tier 1** | 1.5 | NTI Electrolyte Disturbance Monitoring | Digoxin cardiotoxicity risk with hypokalemia ($K^+ < 3.5$) and hypomagnesemia ($Mg^{2+} < 1.7$); Lithium hyponatremia ($Na^+ < 135$) warning | **PASS** |
| **Tier 1** | 1.6 | Weight Selection & Devine IBW | Computes Devine IBW; enforces mandatory AdjBW 0.4 ($IBW + 0.4 \cdot (TBW - IBW)$) for obese patients ($BMI \ge 30$) on aminoglycosides | **PASS** |
| **Tier 1** | 1.7 | Renal Estimation in Special Populations | Cockcroft-Gault with elderly sarcopenia floor ($SCr = 0.8\text{ mg/dL}$ for age $\ge 65$); pediatric Bedside Schwartz with subpopulation constants ($k=0.33, 0.413$) | **PASS** |
| **Tier 1** | 1.8 | High-Alert Infusions Rate Conversion | Norepinephrine standard dilution ($16\text{ mcg/mL}$) rate conversion ($\text{mcg/kg/min} \to \text{mL/hr}$), matching `IvRateCalculator` | **PASS** |
| **Tier 2** | 2.1 | Phenytoin Saturation Guard ($Dose \ge V_{\max}$) | Prevents mathematical division by zero/negative when ordered dose exceeds metabolic capacity, preserving ordered dose per Rule 5 | **PASS** |
| **Tier 2** | 2.2 | Malnutrition / Underweight ($TBW < IBW$) | Enforces Actual Body Weight (TBW) for malnourished patients to prevent toxic 46% aminoglycoside overdose | **PASS** |
| **Tier 2** | 2.3 | Morbid Obesity Mandatory AdjBW 0.4 | Obese patient ($BMI = 37.1$) automatically receives AdjBW 0.4 for aminoglycoside dosing | **PASS** |
| **Tier 2** | 2.4 | Negative & Invalid Input Protection | Throws `ArgumentError` on non-positive or non-finite clinical inputs | **PASS** |
| **Tier 2** | 2.5 | Vasopressor Titration Ceiling Breach | Norepinephrine at $1.5\text{ mcg/kg/min}$ (> $1.0\text{ mcg/kg/min}$ ceiling) preserves pump rate ($393.75\text{ mL/hr}$) with critical alert (Rule 5) | **PASS** |
| **Tier 3** | 3.1 | Sepsis ICU AKI Patient on Vancomycin | Expanded sepsis $V_d = 0.85\text{ L/kg}$, declining CrCl ($30\text{ mL/min}$), and dosage titration targeting $\text{AUC}_{24}/\text{MIC} \in [400, 600]$ | **PASS** |
| **Tier 3** | 3.2 | Obese Diabetic on Gentamicin Hartford | Morbidly obese patient ($120\text{ kg}, BMI = 41.5$) correctly dosed on AdjBW $87.56\text{ kg}$; Hartford nomogram recommends extended q36h interval | **PASS** |
| **Tier 3** | 3.3 | Cirrhotic Hypoalbuminemia on Phenytoin | Patient with Albumin $1.8\text{ g/dL}$ and normal-appearing raw Phenytoin ($14\text{ mcg/mL}$); Sheiner-Tozer exposes severe hidden toxicity ($C_{adj} = 30.43\text{ mcg/mL}$) | **PASS** |
| **Tier 3** | 3.4 | Septic Shock High-Dose Norepinephrine Override | Refractory septic shock requiring $1.8\text{ mcg/kg/min}$; verifies pump rate ($472.5\text{ mL/hr}$) and logs structured `ClinicalOverrideJustification` | **PASS** |
| **Tier 4** | 4.1 | ICU Septic Shock Resuscitation Protocol | Multi-step ICU workflow: Norepinephrine titration, empiric Vancomycin loading dose ($25–30\text{ mg/kg}$), and Red Man Syndrome infusion time guard | **PASS** |
| **Tier 4** | 4.2 | Ward TDM Morning Rounding | Pharmacist rounds: evaluates 8h Hartford Gentamicin level ($7.0\text{ mg/L} \to q24h$); catches and flags premature $2.5\text{h}$ Digoxin draw | **PASS** |
| **Tier 4** | 4.3 | Neonatal / Pediatric Antimicrobial Dosing | 28-week preterm neonate ($1.1\text{ kg}$, $36\text{ cm}$): Bedside Schwartz $k=0.33 \implies eGFR = 16.97\text{ mL/min/1.73m}^2$, safe neonatal Gentamicin dose | **PASS** |

---

## Artifact Index & Directory Layout

```
c:\Users\turbo\drugforPh\
├── TEST_INFRA.md                          # Testing architecture & 4-tier methodology
├── TEST_READY.md                          # This coverage and execution report
└── test/
    └── e2e/
        ├── pk_reference_engine.dart       # Deterministic PK-PD mathematical oracle harness
        ├── specialized_dosing_harness.dart # NTI & Specialized Dosing clinical oracle harness
        ├── e2e_pkpd_modeling_test.dart    # 18 test cases across Tiers 1-4
        └── e2e_specialized_dosing_test.dart # 20 test cases across Tiers 1-4
```

---

## Test Runner Commands

### 1. Run Complete E2E Suite (38 tests)
```powershell
flutter test test/e2e/
```

### 2. Run PK-PD Modeling Suite (18 tests)
```powershell
flutter test test/e2e/e2e_pkpd_modeling_test.dart
```

### 3. Run Specialized Dosing Suite (20 tests)
```powershell
flutter test test/e2e/e2e_specialized_dosing_test.dart
```

### 4. Verify Static Analysis
```powershell
dart analyze test/e2e/
```
*(Result: `No issues found!`)*
